Polo-like kinase 1 inhibitors, mitotic stress and the tumor suppressor p53.
about
Comprehensive genomic characterization of head and neck squamous cell carcinomasPhase I study of oral rigosertib (ON 01910.Na), a dual inhibitor of the PI3K and Plk1 pathways, in adult patients with advanced solid malignanciesAdenovirus replaces mitotic checkpoint controls.Loss of p21Cip1/CDKN1A renders cancer cells susceptible to Polo-like kinase 1 inhibitionB-cell lymphoma 6 promotes proliferation and survival of trophoblastic cellsAberrant DNA Double-strand Break Repair Threads in Breast Carcinoma: Orchestrating Genomic Insult Survival.Remote loading of preencapsulated drugs into stealth liposomes.Battle of the eternal rivals: restoring functional p53 and inhibiting Polo-like kinase 1 as cancer therapy.Current assessment of polo-like kinases as anti-tumor drug targets.Combining p53 stabilizers with metformin induces synergistic apoptosis through regulation of energy metabolism in castration-resistant prostate cancer.Spotlight on Volasertib: Preclinical and Clinical Evaluation of a Promising Plk1 Inhibitor.Functional analysis of phosphorylation of the mitotic centromere-associated kinesin by Aurora B kinase in human tumor cellsp21Waf1/Cip1 deficiency causes multiple mitotic defects in tumor cells.Polo-like kinase 1 inhibition causes decreased proliferation by cell cycle arrest, leading to cell death in glioblastoma.The activity regulation of the mitotic centromere-associated kinesin by Polo-like kinase 1The responses of cancer cells to PLK1 inhibitors reveal a novel protective role for p53 in maintaining centrosome separation.Deficiency of RITA results in multiple mitotic defects by affecting microtubule dynamics.
P2860
Q28256121-56FDA5F1-2454-4151-9E86-4FD5C4B7F192Q34159739-578B063A-F08A-42E3-A56D-181E8088F54FQ35488742-B86F2832-A292-471F-86A4-F062AAB12FE4Q35740037-12FC993E-B5C7-46BF-94E1-500B781F2832Q36839342-9CFFB8D8-183F-455E-A9F4-EB792CBD9CE6Q37552296-9CF68394-EB00-470E-84A3-8A1523C75B46Q37587698-F4BDF008-B39F-4541-B13F-24087F1AFE75Q38129174-D4A7BDDF-E787-4FA5-8A9E-53AE26D3823DQ38211244-0F5F9753-6F77-4E43-8B21-3D7EE152067BQ38792069-963381C5-54AE-48F5-A218-ABFF5021C466Q38824242-89FA3F49-16F5-466A-B729-85F5905C351AQ38856254-709C3B34-EC10-44F5-8214-5D18810B9B31Q39045570-8F18D489-104C-430A-B295-81176734344BQ39120232-4CB51D6C-9D92-498C-B2D7-0645D277F561Q41694208-7265F488-FC7A-4E4E-B65F-76D801F9FDB8Q47135845-88CDC4F7-D190-464E-8A8A-39D17CF7D8C6Q51411634-1CB820BF-8134-4038-8EBF-12FB428C050B
P2860
Polo-like kinase 1 inhibitors, mitotic stress and the tumor suppressor p53.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Polo-like kinase 1 inhibitors, mitotic stress and the tumor suppressor p53.
@en
type
label
Polo-like kinase 1 inhibitors, mitotic stress and the tumor suppressor p53.
@en
prefLabel
Polo-like kinase 1 inhibitors, mitotic stress and the tumor suppressor p53.
@en
P2093
P2860
P356
P1433
P1476
Polo-like kinase 1 inhibitors, mitotic stress and the tumor suppressor p53.
@en
P2093
Brigitte Zimmer
Frank Louwen
Juping Yuan
Mourad Sanhaji
Nina-Naomi Kreis
Susanne Roth
P2860
P304
P356
10.4161/CC.24573
P577
2013-04-10T00:00:00Z